Ahmed Kotb/LinkedIn
Aug 18, 2025, 23:49
Ahmed Kotb: HHT Management—Choosing the Right Therapy?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“HHT management (guideline highlights):
- Epistaxis → Topical + Antifibrinolytics → Anti-angiogenic if refractory
- GI bleed → Grade by iron/RBC needs → (mild) → (moderate–severe)
- Anemia → Screen → Oral iron → IV iron.”
More on coagulation disorders featured in Hemostasis Today.
-
Mar 7, 2026, 16:24Kalpana Gupta Shekhawat: The Overlooked Regulator of Mast Cells – Understanding the Vagus Nerve
-
Mar 7, 2026, 16:20Purusotham Chippala: How DALYs Reveal the True Burden of Stroke
-
Mar 7, 2026, 16:13Ilenia Calcaterra: Patient-Level Real-World Outcomes of Emicizumab in Acquired Hemophilia A
-
Mar 7, 2026, 16:05Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
-
Mar 7, 2026, 15:58Aurelio Maggio: The Mission and The Projects We Are Advancing for Rare Hematologic Diseases
-
Mar 7, 2026, 15:52Faizan Khan: The Importance of Cancer Site in Bleeding Risk Stratification for Cancer-Associated VTE
-
Mar 7, 2026, 15:50Heghine Khachatryan: How DOACs Can Cause False-Positive FVIII Inhibitor Results
-
Mar 7, 2026, 15:43Gevorg Tamamyan Joins The London Global Cancer Week Steering Group
-
Mar 7, 2026, 15:36Kenneth Monaghan: Empowering Stroke Survivors’ Self-Efficacy Through Neuroplasticity and Daily Activity